Tempus AI

Tempus AI CapEx/OCF

The CapEx to Operating Cash Flow Ratio of Tempus AI (TEM) as of Nov 20, 2026 is -12.50 %. In the previous year, CapEx to Operating Cash Flow Ratio was -11.70 % — a change of 6.84% (lower).

CapEx/OCF

-12.50 %

YoY

6.84%

Last updated:

CapEx to Operating Cash Flow Ratio of Tempus AI is 2025 -12.50 % . CapEx to Operating Cash Flow Ratio of Tempus AI was 2024 -11.70 % . It decreases by 6.84% lower compared to the previous year.

The Tempus AI CapEx/OCF history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

CapEx/OCF
Date
CapEx/OCF
Jan 1, 2019
-14.55 USD
Jan 1, 2020
-6.49 USD
Jan 1, 2021
-5.55 USD
Jan 1, 2022
-10.93 USD
Jan 1, 2023
-16.15 USD
Jan 1, 2024
-11.70 USD
Jan 1, 2025
-12.50 USD
The Tempus AI CapEx/OCF history
YEARCapEx/OCFYoY
-12.50 %+6.84%
-11.70 %-27.53%
-16.15 %+47.79%
-10.93 %+96.82%
-5.55 %-14.53%
-6.49 %-55.35%
-14.55 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Tempus AI Stock analysis

What does Tempus AI do? Tempus AI Inc provides next generation diagnostics through genomics, data, and AI applications. Its genomics product line includes next generation sequencing, diagnostics, PCR, profiling, molecular genotyping, and pathology testing. The AI applications focus on algorithmic diagnostics, software as a medical device, and clinical decision support tools. The primary AI product Next uses machine learning to identify care gaps for oncology and cardiology patients. The company serves healthcare providers and life sciences organizations seeking personalized medicine solutions. Tempus AI Inc's revenue comes from its genomics and AI product lines. The genomics services are delivered through its laboratories, offering sequencing, diagnostics, and molecular testing. The AI applications, particularly Next, are sold as software solutions to healthcare institutions. The target customers are healthcare providers and life sciences companies that require advanced diagnostic tools for personalized treatment plans. The company operates in the Life Sciences Tools & Services industry, focusing on oncology and cardiology segments. The company's genomics product line generates revenue through laboratory services for molecular pathology testing. AI applications like Next are sold as medical device software, targeting healthcare institutions for clinical decision support. The primary segments served are oncology and cardiology, where personalized medicine is critical. The company's products are designed to integrate with existing healthcare data systems to improve patient care outcomes. Tempus AI is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Tempus AI stock

CapEx to Operating Cash Flow Ratio of Tempus AI is -12.50 % in 2025.

CapEx to Operating Cash Flow Ratio of Tempus AI changed from -11.70 % to -12.50 %, representing a 6.84% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of CapEx to Operating Cash Flow Ratio Tempus AI since 2006 – with annual values, charts, and detailed analysis.

The CapEx/OCF ratio shows what percentage of operating cash flow is reinvested in capital assets. Lower ratios indicate more free cash available for shareholders.

A 'good' varies by industry and company stage. On Eulerpool, you can compare CapEx to Operating Cash Flow Ratio's Tempus AI with sector peers and the industry average to assess whether it is attractive.

To evaluate CapEx to Operating Cash Flow Ratio's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for CapEx to Operating Cash Flow Ratio.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Cash Flow — Tempus AI

All Key Metrics — Tempus AI